HRP20230458T1 - Piridazinoni kao inhibitori parp7 - Google Patents

Piridazinoni kao inhibitori parp7 Download PDF

Info

Publication number
HRP20230458T1
HRP20230458T1 HRP20230458TT HRP20230458T HRP20230458T1 HR P20230458 T1 HRP20230458 T1 HR P20230458T1 HR P20230458T T HRP20230458T T HR P20230458TT HR P20230458 T HRP20230458 T HR P20230458T HR P20230458 T1 HRP20230458 T1 HR P20230458T1
Authority
HR
Croatia
Prior art keywords
alkyl
nrc3rd3
aryl
ora3
optionally substituted
Prior art date
Application number
HRP20230458TT
Other languages
English (en)
Croatian (hr)
Inventor
Melissa Marie Vasbinder
Laurie B. Schenkel
Kerren Kalai Swinger
Kevin Wayne Kuntz
Original Assignee
Ribon Therapeutics Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribon Therapeutics Inc. filed Critical Ribon Therapeutics Inc.
Publication of HRP20230458T1 publication Critical patent/HRP20230458T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20230458TT 2018-04-30 2019-04-29 Piridazinoni kao inhibitori parp7 HRP20230458T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862664544P 2018-04-30 2018-04-30
PCT/US2019/029582 WO2019212937A1 (en) 2018-04-30 2019-04-29 Pyridazinones as parp7 inhibitors
EP19723272.1A EP3788040B1 (en) 2018-04-30 2019-04-29 Pyridazinones as parp7 inhibitors

Publications (1)

Publication Number Publication Date
HRP20230458T1 true HRP20230458T1 (hr) 2023-07-21

Family

ID=66476851

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20230458TT HRP20230458T1 (hr) 2018-04-30 2019-04-29 Piridazinoni kao inhibitori parp7

Country Status (36)

Country Link
US (6) US10550105B2 (enExample)
EP (2) EP3788040B1 (enExample)
JP (2) JP6942896B2 (enExample)
KR (1) KR102862474B1 (enExample)
CN (2) CN120987912A (enExample)
AR (1) AR121419A1 (enExample)
AU (2) AU2019262927B2 (enExample)
BR (1) BR112020022006A2 (enExample)
CA (1) CA3098585A1 (enExample)
CL (1) CL2020002821A1 (enExample)
CO (1) CO2020013599A2 (enExample)
CR (1) CR20200518A (enExample)
CY (1) CY1126132T1 (enExample)
DK (1) DK3788040T3 (enExample)
EA (1) EA202092590A1 (enExample)
EC (1) ECSP20069404A (enExample)
ES (1) ES2949538T3 (enExample)
FI (1) FI3788040T3 (enExample)
HR (1) HRP20230458T1 (enExample)
HU (1) HUE062096T2 (enExample)
IL (2) IL278116B2 (enExample)
LT (1) LT3788040T (enExample)
MA (1) MA52486B1 (enExample)
MD (1) MD3788040T2 (enExample)
MX (2) MX2020011465A (enExample)
PE (1) PE20211382A1 (enExample)
PH (1) PH12020551760A1 (enExample)
PL (1) PL3788040T3 (enExample)
PT (1) PT3788040T (enExample)
RS (1) RS64283B1 (enExample)
SG (1) SG11202010183XA (enExample)
SI (1) SI3788040T1 (enExample)
SM (1) SMT202300172T1 (enExample)
TW (2) TWI811353B (enExample)
WO (1) WO2019212937A1 (enExample)
ZA (1) ZA202006549B (enExample)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020022006A2 (pt) * 2018-04-30 2021-01-26 Ribon Therapeutics Inc. piridazinonas como inibidores de parp7
US11293927B2 (en) 2018-04-30 2022-04-05 Ribon Therapeutics, Inc. Screening methods for PARP modulators
WO2019241131A1 (en) 2018-06-11 2019-12-19 Pipeline Therapeutics, Inc. Muscarinic acetylcholine m1 receptor antagonists
CN119112895A (zh) 2018-09-04 2024-12-13 康蒂内乌姆医疗公司 毒蕈碱性乙酰胆碱m1受体拮抗剂
MX2021011316A (es) * 2019-03-20 2021-10-13 Goldfinch Bio Inc Piridazinonas y metodos de uso de estas.
WO2020223229A1 (en) * 2019-04-29 2020-11-05 Ribon Therapeutics, Inc. Solid forms of a parp7 inhibitor
IL326597A (en) * 2019-10-07 2026-04-01 Contineum Therapeutics Inc Muscarinic acetylcholine m1 receptor antagonists
WO2021087018A1 (en) * 2019-10-30 2021-05-06 Ribon Therapeutics, Inc. Pyridazinones as parp7 inhibitors
TWI902715B (zh) * 2019-10-30 2025-11-01 美商律幫治療股份有限公司 作為ｐａｒｐ７抑制劑的嗒酮
US11752149B2 (en) 2019-12-02 2023-09-12 Pipeline Therapeutics, Inc. Muscarinic acetylcholine M1 receptor antagonists
JP7842698B2 (ja) * 2020-04-23 2026-04-08 オプナ バイオ ソシエテ アノニム Ｃｄ７３調節のための化合物及び方法並びにそれらの表示
US20230219942A1 (en) * 2020-06-09 2023-07-13 Relive Therapeutics Inc. Compounds comprising a three ring core as pd-1/pd-l1 blockers
KR102873922B1 (ko) * 2020-07-03 2025-10-20 우한 크리에이터나 사이언스 앤드 테크놀로지 컴퍼니, 리미티드 헤테로고리 화합물 및 이의 용도
CN116157396B (zh) * 2020-11-27 2025-07-18 康百达（四川）生物医药科技有限公司 哒嗪酮衍生物及其在医药上的应用
JP7623826B2 (ja) * 2020-12-18 2025-01-29 株式会社 資生堂 Ｔｉｐａｒｐ産生促進剤
WO2022156708A1 (en) * 2021-01-20 2022-07-28 Jacobio Pharmaceuticals Co., Ltd. Parp7 enzyme inhibitor
US20240166664A1 (en) * 2021-02-03 2024-05-23 Shanghai Apeiron Therapeutics Company Limited Triheterocyclic compound, preparation method therefor, and application thereof
US20240317755A1 (en) * 2021-02-07 2024-09-26 Wuhan Ll Science And Technology Development Co., Ltd. Heterocyclic compound, and intermediate thereof, preparation method therefor and use thereof
EP4291560A4 (en) * 2021-02-09 2025-01-15 Jacobio Pharmaceuticals Co., Ltd. TRICYCLIC DERIVATIVES USEFUL AS PARP7 INHIBITORS
EP4294399A1 (en) 2021-02-16 2023-12-27 Ribon Therapeutics Inc. Dosage regimens for parp7 inhibitors
CN115028648B (zh) * 2021-03-03 2024-08-30 武汉誉祥医药科技有限公司 三并环化合物及其药物组合物和应用
WO2022188889A1 (zh) * 2021-03-12 2022-09-15 杭州英创医药科技有限公司 作为parp7抑制剂的化合物
WO2022194122A1 (zh) * 2021-03-16 2022-09-22 上海翰森生物医药科技有限公司 含氮杂环的多环化合物及其制备方法和应用
GB202114315D0 (en) * 2021-10-06 2021-11-17 Duke Street Bio Ltd Pharmaceutical compound
MX2023011378A (es) 2021-03-31 2023-10-06 Duke Street Bio Ltd Compuesto farmaceutico.
WO2022223022A1 (zh) * 2021-04-23 2022-10-27 四川海思科制药有限公司 一种并环杂环衍生物及其在医药上的应用
CN117279917A (zh) * 2021-05-21 2023-12-22 成都百裕制药股份有限公司 哌嗪衍生物及其在医药上的应用
WO2022247839A1 (zh) * 2021-05-25 2022-12-01 山东轩竹医药科技有限公司 Parp7抑制剂
CN115477640A (zh) * 2021-05-31 2022-12-16 由理生物医药（上海）有限公司 作为parp7抑制剂的哒嗪酮类化合物
WO2023001247A1 (zh) * 2021-07-21 2023-01-26 南京明德新药研发有限公司 哒嗪酮类化合物
WO2023001296A1 (zh) * 2021-07-23 2023-01-26 武汉人福创新药物研发中心有限公司 作为parp7抑制剂的哒嗪酮类化合物
WO2023011629A1 (zh) * 2021-08-06 2023-02-09 成都百裕制药股份有限公司 吡咯烷酮衍生物及其在医药上的应用
WO2023020479A1 (zh) * 2021-08-16 2023-02-23 重庆华森制药股份有限公司 Parp7抑制剂及其应用
CN117897380A (zh) * 2021-08-17 2024-04-16 益方生物科技(上海)股份有限公司 哒嗪酮或吡啶酮化合物、其制备方法和用途
EP4423078A1 (en) 2021-10-28 2024-09-04 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
CN115745971B (zh) * 2021-12-20 2024-07-30 北京华森英诺生物科技有限公司 Parp7抑制剂及其应用
CN116375688B (zh) * 2021-12-23 2025-04-11 中国药科大学 哒嗪酮类化合物及其制备方法、药物组合物和应用
CN116444497B (zh) * 2022-01-14 2025-06-24 如东凌达生物医药科技有限公司 一类哒嗪酮类化合物、制备及其应用
WO2023143236A1 (zh) * 2022-01-26 2023-08-03 中国药科大学 2h-吲唑-7-甲酰胺类化合物、制备方法、药物组合物和应用
CN116535395B (zh) * 2022-01-26 2024-07-09 中国药科大学 2h-吲唑-7-甲酰胺类化合物、制备方法、药物组合物和应用
CA3248911A1 (en) 2022-01-28 2023-08-03 Gilead Sciences, Inc. POLY(ADENOSINE DIPHOSPHATE-RIBOSE) POLYMERASE 7 INHIBITORS
WO2023185073A1 (zh) * 2022-04-01 2023-10-05 诺沃斯达药业(上海)有限公司 Parp7抑制剂及其用途
TW202346294A (zh) * 2022-04-21 2023-12-01 大陸商四川海思科製藥有限公司 吡嗪酮衍生物及其在醫藥上的應用
WO2024032410A1 (zh) * 2022-08-09 2024-02-15 成都百裕制药股份有限公司 哌嗪类化合物和pd-1抑制剂或pd-l1抑制剂的组合物以及其治疗肿瘤的用途
CN117586263B (zh) * 2022-08-09 2026-04-10 康百达（四川）生物医药科技有限公司 哌嗪衍生物及其在医药上的应用
EP4570249A4 (en) * 2022-08-09 2026-07-22 Kangbaida Sichuan Biotechnology Co Ltd USE OF A PIPERAZINE COMPOUND IN COMBINATION WITH RADIOTHERAPY FOR THE TREATMENT OF A TUMOR
TW202416984A (zh) * 2022-08-17 2024-05-01 大陸商北京加科思新藥研發有限公司 化合物i或其鹽的固體形式
GB202213819D0 (en) 2022-09-22 2022-11-09 Duke Street Bio Ltd Pharmaceutical compound
CN115490671B (zh) * 2022-10-21 2024-05-14 水木未来(北京)科技有限公司 Parp7抑制剂及其制备方法
CN117551080A (zh) * 2022-11-11 2024-02-13 杭州师范大学 一种靶向降解parp7的protac化合物及其制备方法与应用
TWI879228B (zh) * 2022-11-14 2025-04-01 康百達（四川）生物醫藥科技有限公司 取代的哌衍生物的晶型及其製備方法、藥物組合物和製藥用途
GB202217888D0 (en) 2022-11-29 2023-01-11 Duke Street Bio Ltd Pharmaceutical compound
TW202430518A (zh) * 2023-01-06 2024-08-01 大陸商齊魯製藥有限公司 Parp7抑制劑的製備方法
WO2024149234A1 (en) * 2023-01-10 2024-07-18 Angel Pharmaceutical Co., Ltd. Parp7 inhibitors and uses thereof
WO2024149231A1 (en) * 2023-01-10 2024-07-18 Angel Pharmaceutical Co., Ltd. Parp7 inhibitors and uses thereof
CN118388414A (zh) * 2023-01-17 2024-07-26 中国药科大学 哒嗪酮类化合物及其制备方法、药物组合物和应用
IL326495A (en) * 2023-08-17 2026-04-01 Kangbaida Sichuan Biotechnology Co Ltd Pharmaceutical preparation of piperazine derivative, preparation method therefor, and use thereof
CN117126136B (zh) * 2023-08-25 2026-05-19 安润医药科技（苏州）有限公司 Parp7抑制剂及其应用
CN121752568A (zh) * 2023-08-29 2026-03-27 康百达（四川）生物医药科技有限公司 一种哌嗪衍生物的制备工艺及其中间体
CN122438843A (zh) * 2023-10-26 2026-07-21 奇树医药公司 作为parp7抑制剂的化合物
CN122249234A (zh) * 2023-11-13 2026-06-19 康百达（四川）生物医药科技有限公司 一种parp7抑制剂联合用药的药物组合及其治疗肿瘤的用途
CN117342983B (zh) * 2023-12-05 2024-02-06 康羽生命科学技术(苏州)有限公司 过乙酰化GalNAc-L96合成方法
WO2025209574A1 (zh) * 2024-04-03 2025-10-09 康百达（四川）生物医药科技有限公司 用于预防或治疗肿瘤的parp7抑制剂
CN119684268B (zh) * 2024-12-19 2026-04-03 诺沃斯达药业(上海)有限公司 一种parp7抑制剂的草酸共晶物及其制备方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL110040A (en) * 1993-06-29 2000-07-16 Nissan Chemical Ind Ltd Pyridazinone derivatives their preparation and pharmaceutical compositions comprising them
JP3255293B2 (ja) 1997-09-05 2002-02-12 松下電器産業株式会社 蛍光偏光法
WO2002082082A2 (en) 2001-04-09 2002-10-17 Boehringer Ingelheim Pharmaceuticals, Inc. Fluorescence polarization assay
HU227237B1 (en) * 2001-09-27 2010-12-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Substituted alkylpyridazinone derivatives, process for their preparation, pharmaceutical compositions containing them
GB0301628D0 (en) 2002-09-19 2003-02-26 Aventis Pharma Inc Method for assaying compounds that decrease the activity of poly (ADP-ribose) - polymerase (PARP)
CA2568835C (en) * 2004-06-30 2014-05-27 Janssen Pharmaceutica N.V. Quinazolinone derivatives as parp inhibitors
GB0610680D0 (en) * 2006-05-31 2006-07-12 Istituto Di Ricerche D Biolog Therapeutic compounds
EP2502918B1 (en) 2006-07-25 2015-03-25 Cephalon, Inc. Pyridazinone Derivatives
JP5758630B2 (ja) * 2007-11-15 2015-08-05 エンメエッセディ・イタリア・エッセ・エッレ・エッレ Ｐａｒｐ阻害剤としてのピリダジノン誘導体
DK2271626T3 (en) * 2008-03-27 2015-02-23 Janssen Pharmaceutica Nv TETRAHYDROPHENANTHRIDINONES AND TETRAHYDROCYCLOPENTAQUINOLINONES AS INHIBITORS OF POLYMERIZATION OF PARP AND TUBULIN
NZ623069A (en) * 2009-08-17 2015-11-27 Sloan Kettering Inst Cancer Heat shock protein binding compounds, compositions, and methods for making and using same
CN103570725B (zh) * 2012-08-01 2017-03-22 中国科学院上海药物研究所 哌嗪并三唑类化合物及其制备方法和用途
JO3470B1 (ar) 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
EP2970289A1 (en) * 2013-03-15 2016-01-20 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
WO2016116602A1 (en) * 2015-01-23 2016-07-28 Astrazeneca Ab Treatment of cancer
CN106749261A (zh) * 2015-11-23 2017-05-31 中国科学院上海药物研究所 一类取代三唑并哌嗪类parp抑制剂及其制备方法和用途
TWI785022B (zh) 2017-03-28 2022-12-01 美商富曼西公司 新穎噠嗪酮類除草劑
US12435078B2 (en) * 2017-09-18 2025-10-07 Gfb (Abc), Llc Pyridazinones and methods of use thereof
GB201717080D0 (en) 2017-10-18 2017-11-29 Syngenta Participations Ag Chemical process
US11293927B2 (en) 2018-04-30 2022-04-05 Ribon Therapeutics, Inc. Screening methods for PARP modulators
BR112020022006A2 (pt) 2018-04-30 2021-01-26 Ribon Therapeutics Inc. piridazinonas como inibidores de parp7
WO2020223229A1 (en) 2019-04-29 2020-11-05 Ribon Therapeutics, Inc. Solid forms of a parp7 inhibitor
WO2021087018A1 (en) 2019-10-30 2021-05-06 Ribon Therapeutics, Inc. Pyridazinones as parp7 inhibitors
TWI902715B (zh) 2019-10-30 2025-11-01 美商律幫治療股份有限公司 作為ｐａｒｐ７抑制劑的嗒酮

Also Published As

Publication number Publication date
SMT202300172T1 (it) 2023-09-06
US10870641B2 (en) 2020-12-22
PE20211382A1 (es) 2021-07-27
US11566020B1 (en) 2023-01-31
RS64283B1 (sr) 2023-07-31
EP4234551C0 (en) 2026-06-10
CN120987912A (zh) 2025-11-21
SG11202010183XA (en) 2020-11-27
AU2019262927B2 (en) 2023-11-02
EP3788040A1 (en) 2021-03-10
US20230192664A1 (en) 2023-06-22
MD3788040T2 (ro) 2023-10-31
TWI877697B (zh) 2025-03-21
ECSP20069404A (es) 2021-01-29
LT3788040T (lt) 2023-06-26
ZA202006549B (en) 2025-06-25
KR20210014108A (ko) 2021-02-08
MX2020011465A (es) 2020-12-07
CY1126132T1 (el) 2023-11-15
US20200123134A1 (en) 2020-04-23
PH12020551760A1 (en) 2021-06-28
US20190330194A1 (en) 2019-10-31
TW202014416A (zh) 2020-04-16
US20250034120A1 (en) 2025-01-30
BR112020022006A2 (pt) 2021-01-26
EA202092590A1 (ru) 2021-04-08
US20210024502A1 (en) 2021-01-28
IL308983B2 (en) 2025-10-01
DK3788040T3 (da) 2023-05-08
AU2019262927A1 (en) 2020-11-12
JP6942896B2 (ja) 2021-09-29
JP2022017221A (ja) 2022-01-25
JP7518049B2 (ja) 2024-07-17
ES2949538T3 (es) 2023-09-29
CO2020013599A2 (es) 2020-12-21
IL278116B2 (en) 2024-04-01
SI3788040T1 (sl) 2023-07-31
CN112424188B (zh) 2025-06-27
EP3788040B1 (en) 2023-04-12
EP4234551B1 (en) 2026-06-10
CR20200518A (es) 2021-03-22
IL308983A (en) 2024-01-01
TWI811353B (zh) 2023-08-11
US10550105B2 (en) 2020-02-04
CL2020002821A1 (es) 2021-02-19
IL278116A (en) 2020-11-30
AU2024200566A1 (en) 2024-02-15
WO2019212937A1 (en) 2019-11-07
CA3098585A1 (en) 2019-11-07
CN112424188A (zh) 2021-02-26
KR102862474B1 (ko) 2025-09-24
MX2023005804A (es) 2023-05-29
IL278116B1 (en) 2023-12-01
AU2024200566B2 (en) 2026-03-05
EP4234551A3 (en) 2023-10-11
FI3788040T3 (fi) 2023-06-13
PT3788040T (pt) 2023-07-12
MA52486A (fr) 2021-03-10
TW202344505A (zh) 2023-11-16
EP4234551A2 (en) 2023-08-30
HUE062096T2 (hu) 2023-09-28
IL308983B1 (en) 2025-06-01
US11014913B2 (en) 2021-05-25
JP2021523104A (ja) 2021-09-02
AR121419A1 (es) 2022-06-08
MA52486B1 (fr) 2023-04-28
PL3788040T3 (pl) 2023-08-07

Similar Documents

Publication Publication Date Title
JP2022017221A5 (enExample)
JP7279063B2 (ja) Ｐｄ１／ｐｄ－ｌ１相互作用／活性化の阻害剤としての二環式化合物
JP6741697B2 (ja) 新規なヒドロキシエステル誘導体、その調製方法及びそれを含有する医薬組成物
JP6773695B2 (ja) 新規なヒドロキシ酸誘導体、その製造方法、及びそれを含有する医薬組成物
HRP20220886T1 (hr) Pripravci i postupci za proizvodnju pirimidina i spojeva piridina s btk inhibicijskom aktivnošću
JP2014503567A5 (enExample)
US10662173B2 (en) Indole and pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them
FI3788040T3 (fi) Pyridatsinoneja parp7-inhibiittoreina
ME02838B (me) 3,4-dihidroizokinolin-2(1h)-ilni spojevi
HRP20161203T1 (hr) Novi derivati tienopirimidina, postupak za njihovu pripravu i farmaceutski pripravci koji ih sadrže
JP2020517677A5 (enExample)
AU2015330506A1 (en) EGFR inhibitor, and preparation and application thereof
JP2016053042A5 (enExample)
JP2014518543A5 (enExample)
WO2005033086A1 (en) Compounds and compositions as protein kinase inhibitors
HRP20140437T1 (hr) Bicikliäśki spojevi i njihove uporabe kao dualnih c-src/jak inhibitora
CN116113633B (zh) 一种作为可透脑的btk或her2抑制剂的化合物及其制备方法与用途
JP2011522867A (ja) アザカルボリン誘導体、この調製およびキナーゼ阻害剤としてのこの治療上の使用
WO2023066283A1 (en) Methionine adenosyltransferase 2a (mat2a) inhibitors and uses thereof
JP2013520443A5 (enExample)
JP7035301B2 (ja) 縮合複素環誘導体、その調製方法、及びその医学的使用
HRP20250730T1 (hr) Spoj inhibitor višestruke kinaze, njegov kristalni oblik i upotreba
WO2025038927A1 (en) Modulators of tnf alpha activity and uses thereof
CA2799926A1 (en) Heterocyclic compounds as janus kinase inhibitors
WO2024099168A1 (zh) 一种2,4,5-三取代嘧啶类化合物及其制备方法和用途